Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Geoff Meacham joined J.P. Morgan in 2004 as a senior biotechnology analyst. He previously was an equity analyst at UBS following early stage biotech and life science companies for about four years. Geoff has been ranked for the past five years in the Institutional Investor poll, including a #2 ranking for the past four years. His research coverage spans from large-cap biotech companies with a global reach to small, development stage companies. He has also worked in the pharmaceutical industry for two years in a R&D capacity and he holds a Ph.D. in Cell Biology and a Bachelor of Science in Biology/Microbiology.
Hepatitis C and Orphan Diseases Driving Big Biotech Potential: Geoff Meacham (1/31/12) It may seem counterintuitive that rare diseases might actually be biotech growth drivers, but Senior Analyst and Managing Director Geoff Meacham of JPMorgan Chase makes just that case. In this exclusive interview with The Life Sciences Report, Meacham lays out his premise that hepatitis C and orphan disease drugs can cure the woes of growth-starved investors.
"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico More >
"The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal." (3/5/14) Cancer Genetics Inc. - The Life Sciences Report Interview with Ben Haynor More >
"NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level." (2/27/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Debjit Chattopadhyay More >